Ildong Holdings Co Ltd
Ildong Holdings maintains a capital structure with a debt-to-equity ratio of 1.22, indicating a moderate reliance on debt financing. The company holds KRW 76,380,919,510 in cash and equivalents, but its long-term debt of KRW 205,415,796,600 exceeds its cash reserves, resulting in a net cash position that is negative after subtracting total debt. This suggests potential liquidity risk, as the current ratio is 0.77, below the 1.0 threshold typically considered healthy. Profitability metrics show a return on equity (ROE) of 6.47% and a return on assets (ROA) of 1.36%. These figures are below the industry median for ROE and ROA in the Pharmaceuticals sector, indicating that Ildong Holdings is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is primarily concentrated in its core pharmaceuticals business, with no disclosed segment breakdown. Geographically, Ildong Holdings is heavily exposed to the Korean market, with no material international revenue disclosed. This concentration increases vulnerability to domestic economic and regulatory shifts. Growth trajectory appears modest, with no specific revenue growth rates provided in the latest financials. The company's operating cash flow of KRW 26,864,759,360 and free cash flow of KRW 30,545,833,140 suggest some capacity for reinvestment or shareholder returns, but capital expenditures are negative at KRW -17,893,755,920, indicating asset sales or reduced investment in physical infrastructure. Risk factors include a medium liquidity risk due to the current ratio and net cash position, as well as a low dilution risk based on the absence of significant share issuance activity. The company's debt load and reliance on Korean market conditions are key concerns for investors. Recent filings and transcripts do not indicate any major strategic shifts or material events affecting the company's operations or financial position in the near term. The company continues to operate within its traditional pharmaceuticals and related business lines.
Business. Ildong Holdings Co Ltd is a Korea-based company engaged in the manufacture of pharmaceuticals, including general and specialty drugs, and provides raw materials such as synthesises and probiotics, with operations also extending to advertising, medical equipment distribution, and food processing through its subsidiaries.
Classification. Ildong Holdings is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.
- Ildong Holdings has a debt-to-equity ratio of 1.22, indicating a moderate reliance on debt financing.
- The company's ROE of 6.47% and ROA of 1.36% are below the industry median, suggesting underperformance in capital efficiency.
- Revenue is concentrated in the Korean market, increasing exposure to domestic economic and regulatory risks.
- Free cash flow of KRW 30,545,833,140 provides some flexibility, but capital expenditures are negative, indicating reduced investment.
- Liquidity risk is medium, with a current ratio of 0.77 and a negative net cash position after subtracting total debt.
- No major strategic or financial events have been disclosed in recent filings.
- --
- ## RATIONALES
- Net cash is negative after subtracting total debt.